As of November 6, 2026, Catheter Precision, Inc. has reported one leadership change filing to the SEC under Item 5.02 of Form 8-K, on October 2, 2026 (Form 8-K, October 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Catheter Precision, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Catheter Precision, Inc. reported a change among its directors and officers to the SEC on Form 8-K, Item 5.02, on 2026-10-02. Every row below is cited to the filing it comes from, and this page adds each new change as Catheter Precision, Inc. files it.
Also on the record for Catheter Precision, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 21, 2026 | Stake report, Schedule 13G, by C/M Capital Partners, LP | 9.99% of the class | 5%+ stakes | Source |
| July 20, 2026 | Stake report, Schedule 13G, by SEG JETS SPV I, LLC | 9.79% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by C/M Capital Master Fund, LP | — | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G, by Jonathan Juchno | 9.6% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G, by Gregory Castaldo | 7.5% of the class | 5%+ stakes | Source |
| February 11, 2026 | Stake report, Schedule 13G, by Joseph Reda | 7.5% of the class | 5%+ stakes | Source |
| August 14, 2025 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 4.99% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Catheter Precision, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Catheter Precision, Inc. and the records around it.
Catheter Precision, Inc. elsewhere on the record
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Joseph Reda also filed stake reports on 3 other companies: 22nd Century Group, Inc. (Aug 2026), Datavault AI Inc. (Feb 2026)
- Gregory Castaldo also filed stake reports on 4 other companies: 22nd Century Group, Inc. (Feb 2026), Datacentrex, Inc. (Feb 2026), Datavault AI Inc. (Feb 2026)
- C/M Capital Master Fund, LP also filed stake reports on 8 other companies: Endovia Health Sciences, Inc. (Oct 2026), Volato Group, Inc. (Jul 2026), Beeline Holdings, Inc. (Jun 2026)
Watch Catheter Precision, Inc.
Get an email when Catheter Precision, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Catheter Precision, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on Catheter Precision, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Catheter Precision, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
8 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-02 | Reported | not named in the filing | 8-K, 2026-10-02 |
New leaders reset buying decisions — get the Full Report on Catheter Precision, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the senior executive at Catheter Precision, Inc., with the record behind each one.
Find candidates like senior executive at Catheter Precision, Inc.Every change, in the filing's words
Reported
The Repricing applies to options held by the Company's named executive officers and non-employee directors on the same terms as options held by the Company's other employees and consultants, including options to purchase 89,999 shares of Common Stock held by David A. Jenkins, the Company's Executive Chairman and Chief Executive Officer, and options to purchase 66,315 shares of Common Stock held by Philip Anderson, the Company's Chief Financial Officer, in each case as of August 18, 2026.
- Amendment to 2023 Equity Incentive Plan At the annual meeting of stockholders of Catheter Precision, Inc. (the "Company") held on September 30, 2026 (the "Annual Meeting"), the Company's stockholders approved an amendment (the "Plan Amendment") to the Company's 2023 Equity Incentive Plan (the "2023 Plan") to increase the number of shares of the Company's common stock, par value $0.0001 per share ("Common Stock"), reserved for issuance thereunder by 5,000,000 shares.
- The Company's Board of Directors (the "Board") had previously approved the Plan Amendment, subject to stockholder approval.
- One-Time Repricing of Outstanding Stock Options At the Annual Meeting, the Company's stockholders also approved a one-time repricing (the "Repricing") pursuant to which each outstanding stock option with a per-share exercise price greater than the Fair Market Value (as defined in the 2023 Plan) of the Common Stock on the date of stockholder approval was repriced to equal such Fair Market Value.
- Based on the closing price of the Common Stock on the NYSE American on September 30, 2026, the Fair Market Value, and accordingly the exercise price of each repriced option, is $0.152 per share.
- The Repricing did not change the number of shares subject to any option, its expiration date or its vesting schedule.
Tools for this story
Each opens in a new tab, filled in for Catheter Precision, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.